<DOC>
	<DOCNO>NCT02207634</DOCNO>
	<brief_summary>This study evaluate change time neurocognitive test subject receive statin therapy combination evolocumab ( AMG 145 ) , compare subject receive statin therapy combination placebo .</brief_summary>
	<brief_title>Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth High cardiovascUlar Risk Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Randomized Study 20110118 ( FOURIER ) Current know past diagnosis dementia mild cognitive impairment ( MCI )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Treatment high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>